胰腺癌患者外周血CD4+CD25high调节性T细胞分析

目的：探讨胰腺癌患者外周血高表达CD25的CD4＋调节性T（CD4^＋CD25^highT）细胞比率变化特点及其临床意义。方法：用流式细胞术检测58例胰腺癌患者和14名健康人外周血CD4^＋CD25^highT细胞水平,进行分层分析,初步探讨其表型特征。结果：胰腺癌患者外周血中CD4^＋CD25^highT细胞占CD4^＋T细胞的百分比率为（15.61±13.97）%,明显高于健康人群（2.53±1.26）%（P〈0.01）;CD4＋CD25highT细胞具有调节性T细胞的表面标记特征,即HLA-Ⅰ、CD45 RO阳性,CD45 RA、CD69阴性。人白细胞DR抗原的表达水平在不同个体间的CD4^＋CD25^highT细胞差异较大。这群细胞细胞膜表面共刺激分子CD80、CD86表达水平很低,而共刺激分子CD152（CTLA-4）在不同个体间的CD4^＋CD25^highT细胞差异较大。胰腺癌Ⅰ-Ⅱ期患者,其外周血CD4^＋CD25^highT细胞占CD4^＋T细胞的比率为（18.75±20.76）%;Ⅲ期为（13.71±9.53）%;Ⅳ期为（14.20±7.46）%;各期CD4^＋CD25^highT细胞占CD4^＋T细胞的比率均显著高于健康人群水平（P〈0.01）。结论：胰腺癌患者外周血CD4^＋CD25^highT细胞水平明显升高,可能与肿瘤免疫功能低下及肿瘤发生、发展密切相关。

Analysis of CD4+ CD25high regulatory T cells in peripheral blood of patients with pancreatic carcinoma

Objective：To measure the amount of CD4＋ CD25high regulatory T cells in the circulation of patients with pancreatic carcinoma.Methods：The amount of Treg cells in the peripheral blood of 58 cancer patients and 14 healthy controls was determined by flow cytometry.The phenotype of Treg was also determined by flow cytometry.Results：Compared with healthy controls（2.53±1.26）%,the amount of Treg cells in the peripheral blood of patients with pancreatic carcinoma was increased（15.61±13.97）%（P〈0.01）.Compared with healthy controls,the proportions of Treg cells in the patients with pancreatic carcinoma in stage Ⅰ-Ⅱ（18.75±20.76）%,stage Ⅲ（13.71±9.53）%,stage Ⅳ（14.20±7.46）%,were significantly higher（P〈0.01）.In addition,the Treg cells had high expression of CD45 RO combined with low expression of CD45RA.The costimulatory molecules CD80,and CD86 were not detected on the surface of Treg cells,whereas CD152（CTLA-4） was variably expressed.Some of the Treg cells had surface expression of HLA-DR.The marker of recent activation（CD69） was not found on the surface of Treg cells whereas HLA-Ⅰ was highly expressed on the surface of Treg cells.Conclusions：The amount of Treg cells is increased in the peripheral blood of patients with pancreatic carcinoma.These Treg cells may mitigate the immune response against cancer,and may be related to tumor progress in patients with pancreatic carcinoma.